PMID- 30278578
OWN - NLM
STAT- MEDLINE
DCOM- 20181011
LR  - 20181114
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 39
DP  - 2018 Sep
TI  - The clinical application value of the plasma copeptin level in the assessment of 
      heart failure with reduced left ventricular ejection fraction: A cross-sectional 
      study.
PG  - e12610
LID - 10.1097/MD.0000000000012610 [doi]
LID - e12610
AB  - This study aimed to evaluate the clinical applicability of the plasma copeptin 
      level to assess heart failure with reduced left ventricular ejection fraction 
      (HFrEF).One hundred thirty-one patients with HFrEF, 127 patients with heart 
      failure with preserved left ventricular ejection fraction (HFpEF), and 119 
      healthy candidates were involved. The basic data and examination results of 
      patients were collected. The heart function of the patients with HFrEF and HFpEF 
      were graded on the basis of the criteria of New York Heart Association (NYHA) 
      classification. The plasma copeptin and N-terminal pro-B-type natriuretic peptide 
      (NT-proBNP) levels were tested using enzyme-linked immunosorbent assays 
      (ELISAs).The copeptin and NT-proBNP levels were higher in the HFrEF group than in 
      the HFpEF group. The copeptin and NT-proBNP values increased as the NYHA grade 
      increased in the patients with HFrEF. However, for the patients with HFpEF, the 
      copeptin levels did not change markedly as the NYHA grade increased. The copeptin 
      levels were positively correlated with the NT-proBNP levels in the patients with 
      HFrEF; however, there was no correlation between the copeptin and NT-proBNP 
      values in the patients with HFpEF.Copeptin is involved in the process of 
      progression in patients with HFrEF and the copeptin values might be useful for 
      HFrEF prediction and assessment in the clinic.
FAU - Xu, Lei
AU  - Xu L
AD  - Department of Cardiology, Chinese People's Liberation Army General Hospital, 
      Beijing.
AD  - Department of Internal Medicine, School Hospital of Beihua University, Jilin, 
      China.
FAU - Liu, Xiaoming
AU  - Liu X
AD  - Department of Internal Medicine, School Hospital of Beihua University, Jilin, 
      China.
FAU - Wu, Shuo
AU  - Wu S
AD  - Department of Internal Medicine, School Hospital of Beihua University, Jilin, 
      China.
FAU - Gai, Luyue
AU  - Gai L
AD  - Department of Cardiology, Chinese People's Liberation Army General Hospital, 
      Beijing.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Glycopeptides)
RN  - 0 (Peptide Fragments)
RN  - 0 (Protein Precursors)
RN  - 0 (copeptins)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Cross-Sectional Studies
MH  - Disease Progression
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Glycopeptides/*blood
MH  - Heart Failure/blood/*diagnosis/*physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Peptide Fragments/blood
MH  - Prospective Studies
MH  - Protein Precursors/blood
MH  - Ventricular Dysfunction, Left/blood/*physiopathology
PMC - PMC6181596
COIS- The authors declare no conflicts of interest.
EDAT- 2018/10/04 06:00
MHDA- 2018/10/12 06:00
PMCR- 2018/09/28
CRDT- 2018/10/04 06:00
PHST- 2018/10/04 06:00 [entrez]
PHST- 2018/10/04 06:00 [pubmed]
PHST- 2018/10/12 06:00 [medline]
PHST- 2018/09/28 00:00 [pmc-release]
AID - 00005792-201809280-00100 [pii]
AID - MD-D-18-04308 [pii]
AID - 10.1097/MD.0000000000012610 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Sep;97(39):e12610. doi: 10.1097/MD.0000000000012610.